Dasatinib causes redistribution of lymphocytes and spleen shrinkage. (A) Experimental layout for the 3-day consecutive treatment with dasatinib. (B) Images from 1 representative experiment and spleen areas quantified using FIJI. Analyzed by Kruskal-Wallis test. (C) Endogenous B- and T-cell numbers are expressed as percentage of cells recovered from DMSO-treated mice. For blood, the fold change (FC) between posttreatment and pretreatment samples in dasatinib-treated mice was normalized to that of the control mice (dotted line). n = 4 to 5 mice per group from 2 independent experiments; analyzed by 1-sample t test. (D) Representative confocal images from spleens of DMSO- or dasatinib-treated mice stained for B cells, T cells, or alpha-smooth muscle actin⁺ (α-SMA⁺) cells. The proportional area with respect to the total surface of the section was quantified with FIJI (4′,6-diamidino-2-phenylindole [DAPI] staining represents 100%). Data pooled from at least 2 sections per mouse and a minimum of 3 mice per group. Scale bars represent 500 μm. Analyzed using analysis of variance followed by Tukey multiple comparison test. ∗P < .05; ∗∗P < .01; ∗P < .05; ∗∗∗P < .001; ∗∗∗∗P < .0001. Boxplots depict 25th and 75th percentiles and the median, and the whiskers show fifth and 95th percentiles.